A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Disease Sites:

Thyroid

Staging:

Phase III

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics

Drugs:

Cabozantinib, Dabrafenib, Trametinib, XL184

Principal Investigator(s):

Choe, Jennifer

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

06-09-2025

Trial Type:

Treatment

Protocol ID:

ECOGHNEA3231

National Clinical Trial ID:

NCT06475989

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available